Cairn Data raises $48 million Series B as enterprises face AI compliance deadlines

Cairn Data raised a $48 million Series B on Tuesday, adding new lead investor Harborline Capital as it scales software that helps banks and healthcare groups deploy AI under regulatory controls. The New York based company said the cash will fund go to market hiring in North America and Europe and product work tied to the EU AI Act and US sector rules.

The timing reflects an enterprise shift from pilots to production for AI systems, driven by enforcement calendars and board level risk reviews. Investors are concentrating on software that converts compliance mandates into purchase orders, rather than broad model tooling with unclear budgets.

Harborline led the round with participation from existing investors Echelon Ventures, Quarry Capital, and Driftwood Partners, according to the company. Cairn Data did not disclose valuation, but said the round was an upround from its 2024 Series A.

The company sells a control plane that sits in a customer’s virtual private cloud. It enforces data access policies, tracks lineage and consent, binds datasets to model versions, and produces audit trails for both internal risk teams and external regulators.

Cairn Data reports 34 enterprise customers across financial services and healthcare, with 125 percent net revenue retention and an average contract value of $540,000. The company cited a nine month payback period on new deployments and gross margins near 70 percent.

Competitors include data governance vendors like Immuta and Privacera and AI risk platforms used for validation and monitoring. Cairn Data positions itself at the enforcement layer inside customer environments, which can reduce procurement friction in regulated settings that avoid shared services.

Why this deal matters now Banks face model risk guidance from the Federal Reserve and the OCC that covers generative systems. The EU AI Act begins phased obligations for high risk use cases, with documentation, human oversight, and incident reporting. Healthcare buyers are extending HIPAA interpretations to model training and inference, which raises the bar on consent tracking and data residency.

The investor roster signals continued appetite for AI infrastructure that attaches to existing compliance budgets and shows clear unit economics. It also illustrates a split in AI funding, where agent startups still find attention but governance and data control win approvals from risk committees that control spend.

For the broader tech stack, the deal underscores a rotation to enterprise AI pick and shovel layers that harden deployments behind the firewall. As vendors chase inference efficiency and model quality, capital is also flowing to the systems that make those models auditable and allowed to run at all.